M
Maverick Capital, Ltd.
+ HoldingABVX
+6.18%
3M Return
$93.490
+0.907 (+0.97%)At close
Loading chart…
- High
- 96.390
- Open
- 93.860
- VWAP
- 94.31
- Volume
- 948.09K
- Mkt Cap
- —
- Low
- 93.050
- Amount
- 89.41M
- EV/EBITDA, TTM
- -1.24
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
AI analysis of Abivax SA (ABVX)
SellAbivax SA is not a good buy right now due to its current price of $88.13, which is significantly below the average analyst price target of $155. The company has a negative forward P/E ratio of 0, indicating uncertainty in future earnings. Additionally, the stock has seen a substantial year-to-date decline of 34.12%, raising concerns about its short-term performance and market sentiment.
Valuation Metrics
The current forward P/E ratio for Abivax SA (ABVX) is 0.00, compared to its 5-year average forward P/E of -9.22.
Whales holding ABVX
Events Timeline
News
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
6.009-10CNBCLatest Wall Street Ratings Overview
9.008-04Yahoo FinanceEvexta Bio Partners with Roche for Breast Cancer Clinical Trial
8.507-30NewsfilterAbivax Announces Positive Pre-NDA Interaction with FDA for Obefazimod
- 8.507-30Newsfilter
Abivax Annual Meeting Highlights and Future Outlook
ABVX FAQ — answered by Alphio AI
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others. It operates in the Healthcare sector.
Abivax SA is not a good buy right now due to its current price of $88.13, which is significantly below the average analyst price target of $155. The company has a negative forward P/E ratio of 0, indicating uncertainty in future earnings. Additionally, the stock has seen a substantial year-to-date decline of 34.12%, raising concerns about its short-term performance and market sentiment.
Community
More ↗
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.